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A B S T R A C TObjectives: To estimate the cost-effectiveness of cetuximab mono-
therapy, cetuximab plus irinotecan, and panitumumab monotherapy
compared with best supportive care (BSC) for the third and subse-
quent lines of treatment of patients with Kirsten rat sarcoma wild-
type metastatic colorectal cancer from the perspective of the UK
National Health Service. Methods: An ‘‘an area under the curve’’ cost-
effectiveness model was developed. The clinical effectiveness evi-
dence for both cetuximab and panitumumab was taken from a single
randomized controlled trial (RCT) in each case and for cetuximab plus
irinotecan from several sources. Results: Patients are predicted to
survive for approximately 6 months on BSC, 8.5 months on panitu-
mumab, 10 months on cetuximab, and 16.5 months on cetuximab
plus irinotecan.
Panitumumab is dominated, and cetuximab is extended domi-
nated. An incremental cost-effectiveness ratio (ICER) of £95,000 per
quality-adjusted life-year (QALY) was estimated for cetuximab versus
BSC and is likely to be relatively accurate, because the relevant clinicalsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.11.001
oyle@pms.ac.uk.
ndence to: Martin Hoyle, Peninsula Technology A
lmon Pool Lane, Exeter EX2 4SG, UKevidence is taken from a high-quality RCT. The estimated ICER for
panitumumab versus BSC, at £187,000 per QALY, is less certain due to
assumptions in the adjustment for the substantial crossing-over of
patients in the RCT. The ICER for cetuximab plus irinotecan versus
BSC, at £88,000 per QALY, is least certain due to substantial uncer-
tainty about progression-free survival, treatment duration, and overall
survival. Nonetheless, when key parameters are varied within plau-
sible ranges, all three treatments always remain poor value for money.
Conclusions: All three treatments are highly unlikely to be consid-
ered cost-effective in this patient population in the United Kingdom.
We explain how the reader can adapt the model for other countries.
Keywords: cetuximab, colorectal cancer, cost-effectiveness, cost-
utility, decision analytic modeling, Erbitux, irinotecan,
panitumumab, Vectibix.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Colorectal cancer is a malignant neoplasm arising from the lining
of the large intestine (colon and rectum). In the United Kingdom,
approximately 41,000 new cases were diagnosed in 2009 [1].
Cancer cells eventually spread to nearby lymph nodes (local
metastases), and subsequently to more remote lymph nodes
and other organs in the body. The liver and the lungs are
common metastatic sites of colorectal cancer. This is described
as Stage IV of the American Joint Committee on Cancer tumor
node metastases system or Stage D of the modified Dukes’
classification. The 5-year survival rate of patients with advanced
disease (modified Dukes’ D) is less than 7% [2].
Individuals with metastatic disease who are sufficiently fit
(World Health Organization performance statusr2) are usually
treated with active chemotherapy as first- or second-line therapy.
First-line active chemotherapy options include infusional
5-fluorouracil plus folinic acid (5-FU/FA); oxaliplatin plus infu-
sional 5-FU/FA (FOLFOX); and irinotecan plus infusional 5-FU/FA(FOLFIRI); oral analogues of 5-FU (capecitabine and tegafur with
uracil) may also be used instead of infusional 5-FU. Current
evidence indicates that the use of 5-FU, oxaliplatin, and irinote-
can in any sequence within patients’ care pathway has survival
advantages [3].
More recently, targeted agents have become available includ-
ing anti–epidermal growth factor receptor (EGFR) agents, for
example, cetuximab and panitumumab, and anti–vascular epi-
dermal growth factor receptor agents, for example bevacizumab.
The EGFR signaling pathway has been the focus of new drug
development for colorectal cancer because it is overexpressed in
approximately 80% of colorectal carcinomas. Kirsten rat sarcoma
(KRAS) mutation status—wild type or mutant—can explain resis-
tance to anti-EGFR therapy. In colorectal cancer, approximately
65% of the patients are KRAS wild type and the remaining 35%
are KRAS mutant [4].
As far as we are aware, there are no fully published studies of
the cost-effectiveness of panitumumab or cetuximab plus irino-
tecan for third and subsequent lines of treatment of patients withSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ssessment Group (PenTAG), Medical School, University of Exeter,
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effectiveness analyses of cetuximab versus best supportive care
(BSC) in Canada by Mittmann et al. [5] and in Switzerland by
Blank et al. [6] are the only fully published studies of the cost-
effectiveness of cetuximab in this setting. The manufacturers of
cetuximab (Erbitux, Merck Serono, Geneva, Switzerland) and
panitumumab (Vectibix, Amgen, Thousand Oaks, CA) recently
made submissions to the National Institute for Health and
Clinical Excellence (NICE) in the United Kingdom [7]. Merck
Serono submitted cost-effectiveness analyses of cetuximab ver-
sus BSC and cetuximab plus irinotecan versus BSC. Here, we
estimate the cost-effectiveness of cetuximab, cetuximab plus
irinotecan, panitumumab, and BSC for third and further lines
of treatment of metastatic colorectal cancer. Our analysis is
restricted to KRAS wild-type patients , because post hoc analyses
suggest that the clinical benefit of cetuximab and panitumumab
is confined to these people [8,9].Methods
Model Structure
The structure of the model, which was informed by a review of
the literature and expert opinion, is simple and has often been
used to simulate the progression of metastatic cancers. Three
health states are used to represent the progression of metastatic
colorectal cancer: progression-free survival (PFS), progressive
disease (PD), and death. At the end of each cycle, people either
remain in their current health state or move to a more severe
state. All people enter the model either receiving a third or
subsequent line of treatment or BSC. After treatment disconti-
nuation, no further lines of drug treatment are modeled.
An ‘‘area under the curve’’/‘‘partitioned survival’’ Markov-type
model (see, e.g., Hoyle et al. [10]) was developed to model disease
progression and treatment effectiveness. The number of patients in
PFS and overall survival (OS) at any time is determined directly
from the underlying survival curves, and the time in PD is
calculated as OS minus PFS. This was preferred to a conventional
Markov approach for two reasons. First, it bypasses the need to
estimate transition probabilities between health states, and second,
it avoids the need for additional assumptions, such as whether
death was permitted from both PFS and PD. The model was written
in Microsoft Excel (Microsoft Corporation, Redmond, WA).
The model cycle length is 1 month, a half-cycle correction is
applied, and the time horizon is 10 years, after which time
virtually all people have died. Future costs and benefits are
discounted at 3.5% per year, and the perspective is that of the
National Health Service (NHS) and Personal Social Services, in
accordance with the NICE Reference Case [11].
Clinical Effectiveness Data
The clinical effectiveness of all treatments was informed by a
systematic search of the literature [12]. Data for cetuximab were
taken from the KRAS wild-type patients in the randomized con-
trolled trial (RCT) of cetuximab versus BSC [8], for panitumumab
from the KRAS wild-type patients in the RCT of panitumumab
versus BSC [9], and for cetuximab plus irinotecan from several
sources: the ‘‘BOND’’ RCT of cetuximab plus irinotecan versus
cetuximab [13] and the observational studies by De Roock et al.
[14,15] and Lievre et al. [16]. Patient baseline characteristics were
similar across the trials: the median age varied from 59 to 63 years,
all or almost all patients had previously had two or more prior
chemotherapies in the panitumumab versus BSC and cetuximab
versus BSC RCTs, and the great majority of patients had had two or
more prior chemotherapies in the cetuximab plus irinotecan versuscetuximab RCT. All or almost all patients had previously taken
irinotecan and oxaliplatin in the panitumumab verus BSC and
cetuximab versus BSC RCTs and in the cetuximab plus irinotecan
versus cetuximab RCT. All patients in all trials had previously taken
irinotecan, and most had previously taken oxaliplatin.
PFS and OS
Given that there is no single RCTwith all treatment groups, it was
necessary to perform an indirect comparison. For PFS, OS, and
mean time on drug treatment, the baseline treatment for the
indirect comparison was BSC taken from the RCT of cetuximab
versus BSC [8]. The clinical effectiveness of people on BSC is also
available from the RCT of panitumumab versus BSC [9]. This,
however, was not considered appropriate for the baseline treat-
ment because the effectiveness of this treatment group was
confounded by substantial crossover (76% of the patients receiv-
ing BSC crossed treatment arms to receive panitumumab) [9]. The
implicit assumption is that the baseline patient characteristics in
the two RCTs are reasonably similar, and indeed this is true [12].
The estimated mean PFS and OS for BSC and for cetuximab
were all taken from analysis of the individual patient data from
the RCT of cetuximab versus BSC by Merck Serono [12]. The mean
is the most important summary statistic of survival given that
cost-effectiveness is a function of mean survival. In Merck Serono’s
analysis, almost no extrapolation was necessary for PFS because
almost all patients had progressed before the end of the study, but
some extrapolation was necessary for OS [8]. Next, Weibull func-
tions were fit to estimate the shape parameters. For estimates of
uncertainty for all parameters in the model, see Hoyle et al. [12].
The mean PFS for panitumumab for the indirect comparison
was calculated by using the Bucher method [17] as the mean PFS
for panitumumab from the RCT of panitumumab versus BSC
multiplied by the ratio of the mean PFS for BSC from the RCT of
panitumumab versus BSC and the mean PFS for BSC from the
RCT of cetuximab versus BSC [12]. The mean OS for panitumu-
mab was calculated in a similar manner as the PFS, with the
adjustment for the indirect comparison. In this case, the mean
OS for BSC in the panitumumab versus BSC RCT was reduced by
2.7 months to allow for the substantial crossover of patients from
the BSC to the panitumumab arm, where the 2.7 months was
calculated by Amgen, the manufacturer of panitumumab [12].
The pivotal BOND trial of cetuximab plus irinotecan versus
cetuximab [13] did not have KRAS status as a prerequisite for
recruitment, and no retrospective KRAS analysis has been sys-
tematically undertaken. Given that we do not have direct rando-
mized evidence for PFS, time on treatment, and OS for KRAS wild-
type patients on cetuximab plus irinotecan, these quantities were
estimated. Details of the methods are given in Hoyle et al. [12].
Treatment Duration
The mean duration of drug treatment is a key determinant of the
mean drug acquisition costs, and therefore of cost-effectiveness.
Ideally, we would model the mean duration of treatment as
experienced in the RCTs. Indeed, this is reported as 10 treatment
cycles for patients with KRAS wild-type status on panitumumab
[9], which we adjusted for the indirect comparison by multiplying
by the ratio of the estimated mean PFS for panitumumab for the
indirect comparison and the mean PFS for panitumumab from
the RCT, leading to a mean duration of 6 months.
The mean duration of treatment is not reported for patients
with KRAS wild-type status on cetuximab or on cetuximab
plus irinotecan. Mittmann, however, informs us that the mean
duration of cetuximab treatment for KRAS wild-type people was
18.9 weeks in the RCT of cetuximab versus BSC [8] (N. Mittmann,
personal communication, May 24, 2011). From this, we estimate a
Table 1 – Utilities used in the model.
Progression-free survival Progressive disease
Mean
(SE)
Correlation Source
Mean
(SE)
Correlation Source
BSC 0.75 (0.08) Baseline
CET RCT
0.69 (0.07)
Correlated with
BSC PFS
CET RCT
Cetuximab 0.78 (0.08)
Correlated with
BSC PFS
CET RCT adjusted
0.69 (0.07)
Set equal to BSC
PD
CET RCT
adjusted
Panitumumab 0.78 (0.08)
Correlated with
BSC PFS
PAN and CET RCTs
adjusted 0.69 (0.07)
Set equal to BSC
PD
CET RCT
adjusted
Cetuximab plus
irinotecan
0.75 (0.08)
Set equal to BSC
PFS
Clinical judgment
0.69 (0.07)
Set equal to BSC
PD
CET RCT
adjusted
BSC, best supportive care; CET, cetuximab; PAN, panitumumab, PD, progressive disease; PFS, progression-free survival; SE, standard error.
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the cetuximab arm (see online Appendix in Supplemental
Materials found at http://dx.doi.org/%2010.1016/j.jval.2012.11.001).
In the pivotal trials of cetuximab versus BSC [8], panitumumab
versus BSC [9], and cetuximab plus irinotecan versus cetuximab
[13], all drugs were taken until disease progression, intolerable
adverse events, or death. Furthermore, in the RCT of cetuximab
versus BSC, cetuximab was taken for approximately the entire
duration of PFS. Given further that the median PFS for all patients
(KRAS wild-type and mutant-type combined) in the cetuximab plus
irinotecan treatment group was 17.8 weeks and the median
number of cetuximab doses in the cetuximab plus irinotecan
treatment group was virtually identical, at 18 [13], we assumed
that cetuximab plus irinotecan was taken for the duration of PFS.
This estimate, however, is clearly subject to substantial uncertainty.
Utilities
For BSC, mean utilities were taken directly from those estimated
by Merck Serono: 0.75 in PFS and 0.69 in PD, measured by the
health utilities index 3 in the RCT of cetuximab versus BSC [8]
(Table 1). In their submission to NICE, Merck Serono estimated a
mean utility for cetuximab in PFS of 0.81 [12]. We capped this
value at 0.78, the mean utility of a 70-year-old member of the
general population of England and Wales [18]. Given a lack of
suitable empirical evidence, the estimated utility for people in
PFS on panitumumab was also set at 0.78. Next, we adjusted
down Merck Serono’s estimate of the mean utility in PD in the
cetuximab arm from 0.79 to 0.69, equal to that in the BSC arm.
The mean utility for people in PFS taking cetuximab plus
irinotecan was estimated at 0.75, equal to the utility for people
in PFS in the BSC group and lower than the value of 0.81 chosen
by Merck Serono [12]. Quality of life is influenced by both tumor
mass and drug toxicity. On the one hand, we might expect theTable 2 – Drug prices used in the model.
Dose and frequency Price
Cetuximab (Erbitux)
Initially 400 mg/m2 body area,
followed by weekly 250 mg/m2
£136.50 per 20-ml (100-mg
£682.50 per 100-ml (500-m
Panitumumab (Vectibix)
6 mg/kg every 2 wk 20 mg/ml, net price
5-ml vial ¼ £379.29,
20-ml vial ¼ £1517.16
Irinotecan (generic)
180 mg/m2 body area every 2 wk 2-ml vial, 20 mg/ml ¼ £4utility for people in PFS on cetuximab plus irinotecan to be higher
than for patients in PFS in the BSC group because the tumor mass
for patients on cetuximab plus irinotecan is, on average, smaller
than for patients on BSC. On the other hand, one might expect
the utility to be lower because irinotecan is a toxic chemotherapy.
It is difficult to estimate the net effect, but in the MABEL single-
arm study of cetuximab plus irinotecan, the mean utility, as
assessed by the EuroQol five-dimensional questionnaire, was 0.75
[19], which equals our estimate of 0.75. For consistency with the
other treatment arms, the mean utility in PD in the cetuximab
plus irinotecan treatment group was set at 0.69.
Disutilities due to adverse events from drug treatment were
not modeled explicitly, rather indirectly via utilities specific to
each treatment.
Costs of Drug Acquisition
Table 2 presents the drug prices, which have been taken from BNF
63 [20], for panitumumab and irinotecan. The price of cetuximab,
which is 23% lower than the list price of £178.10 per 20-ml (100-
mg) vial, £890.50 per 100-ml (500-mg) vial [20], was provided by
Merck Serono, as a Patient Access Scheme. Irinotecan was
assumed given in a 180 mg/m2 dose every 2 weeks. The generic
price of irinotecan was assumed, although the price of the
branded version is only slightly higher at £53 per 2-ml vial [20].
All drugs are given intravenously in fixed vial sizes, and the
total wastage of all drugs that remain in vials at the end of the
infusion for each patient was assumed. The doses of cetuximab
and irinotecan are given proportional to body surface area. It is
common practice in economic analyses to assume that the body
surface areas of all patients are the same. However, in reality
weights, heights and surface areas vary across people, and so the
amount of drug wastage will also vary. As suggested by Sacco et al.
[21], this was captured by modeling the distribution of body surfaceCost per month model cycle
No vial wastage With vial wastage
) vial, £3108 first month, £3421 first month,
g) vial £2730 subsequently £3026 subsequently
£3693 £4104
9.03 £882 £935
Table 3 – Dose intensities used in the model.
Drug
Treatment arm Mean dose
intensity
Standard
error
Source
Cetuximab Cetuximab 92% 0.8%
N. Mittman (personal communication,
May 24, 2011)
Cetuximab Cetuximab plus irinotecan 94% 1.6% Merck Serono [12]
Irinotecan Cetuximab plus irinotecan 90% 2.0% Merck Serono [12]
Panitumumab Panitumumab 100% 0.0% Amgen [12]
* For second and later doses.
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for colorectal cancer. The total drug used, including wastage, was
then calculated for each patient in this range, and then the average
of these dosages was taken, giving a mean dose of cetuximab of
511 mg and of irinotecan of 352 mg. For details, see Hoyle et al. [12].
The dose of panitumumab is proportional to weight, not body
surface area. Allowing for the distribution of body weights across
patients, the estimated mean dose of panitumumab was 499 mg.
For consistency between the costs of the drugs and the clinical
outcomes, it is necessary to model the amounts of the drugs
actually taken in the relevant clinical trials. The dose intensity of a
drug is defined as the amount of drug administered in a trial as a
proportion of the amount that would have been administered if
there had been no dose reductions or dose interruptions. Mean
dose intensities per person used in the model are given in Table 3.
Costs of Other Resources
In addition to drug acquisition, the following costs were modeled:
KRAS testing, drug administration, consultant outpatient visits,
computed tomography scans, BSC in PD, and treatment for
adverse events. All costs are inflated to 2011-2012 values where
appropriate, and the perspective for costs is that of the UK NHS
and Personal Social Services.
The total cost of the KRAS test per person is calculated as £296,
which equals the cost of a test (£160 [22]) divided by the proportion of
people who are KRAS wild-type (54%, provided by Merck Serono [12]),
given that all patients, both wild type and mutant type, are tested.
The cost is very low compared with the costs of drug acquisition.
The cost of £227 in 2008-2009 prices was assumed for the
intravenous administration of cetuximab monotherapy and pani-Table 4 – Medical management costs.
Health
state
Population Frequency Mean
cost
Mean co
per 1- m
model cy
Consultant outpatient visits
PFS During all
active drug
treatment
1 visit per 2
wk
£136
per
visit
£295
BSC group Never £0
CT scans
PFS During all
active drug
treatment
Every 3 mo
£112
per
scan
£37
BSC group Never £0
Medication, hospitalizations, hospice stays, outpatient visits, scans, and
PD All treatment
groups
NA £1039
BSC, best supportive care; CT, computed tomography; NA, not applica
progressive disease; PFS, progression-free survival.tumumab, corresponding to the HRG SB15Z ‘‘Deliver subsequent
elements of a Chemotherapy cycle,’’ ‘‘Outpatients,’’ from the NHS
Reference Costs 2008-2009 [23]. Nondrug NHS costs have typically
increased at approximately 4% per annum over the last 5 years
[24]. Inflating at 4% per annum, from 2008-2009 to 2011-2012,
gives £255 per administration. For patients in the cetuximab plus
irinotecan group, when irinotecan is administered (every 2
weeks), it is given during the same visit to the hospital as
cetuximab (every week). A cost of £255 was assumed for the
administration of cetuximab, and half this amount, £128, for the
subsequent administration of irinotecan [12]. The total pharmacy
cost for the preparation of one infusion for all drugs was
estimated at £15 [12].
The estimated costs of resource use are given in Table 4. The
estimated cost of medical management (medication, hospitaliza-
tions, hospice stays, outpatient visits, scans, and laboratory tests)
for all treatment groups in PD was taken from a study of UK patients
with breast cancer [25], with the assumption that once off active
drug treatment, at the end stage of metastatic cancer, resources to
alleviate pain and other symptoms are similar across cancer types.
The estimated per-patient costs of treating adverse events
were based on those calculated by Merck Serono and were £3671
for cetuximab and for cetuximab plus irinotecan and £2760 for
BSC and for panitumumab [12].
Sensitivity Analyses
One-way sensitivity analyses and probabilistic sensitivity ana-
lyses were performed by varying effectiveness, utility, and cost
parameters. One thousand simulations of the model were run in
the probabilistic sensitivity analysis.st
o
cle
Source
£121 per visit, National Schedule of Reference Costs
Year: ‘‘2008-09’’— NHS trusts and PCTs combined
Consultant Led: Follow-up attendance nonadmitted
face-to-face service code 370: Medical oncology [23]
£136 inflated to 2011–2012 at 4% per annum [24]
£100 [23] National Schedule of Reference Costs Year:
‘‘2008-09’’— NHS trusts and PCTs combined Diagnostic
imaging: Outpatient CT scan, one area, no contrast.
Currency code RA08Z. £112 inflated to 2011–2012 [24]
laboratory test
£675 [25] inflated by 4% per annum from 2000 to 2011
ble; NHS, National Health Service; PCTs, primary care trusts; PD,
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Base Case
Virtually all patients are predicted to have died 3 years from start
of treatment. Average PFS is estimated to be least for people
under BSC (0.23 years ¼ 2.7 months), greater for cetuximab and
panitumumab (0.40 and 0.42 years, respectively, approximately 5
months), and greatest for cetuximab plus irinotecan (0.73 years ¼
8.8 months) (Table 5). Drugs are assumed to be taken approxi-
mately until progression, with cetuximab monotherapy taken forTable 5 – Base-case results for patients with KRAS WT m
Cetuximab Panitu
Life-years (mean, undiscounted)
Time on drug treatment 0.36
Progression free 0.40
Postprogression 0.44
Total (mean) 0.84
Total (median) 0.75
QALYs (mean, discounted)
Progression free 0.31
Postprogression 0.29
Total 0.60
Costs (mean, discounted) (£)
KRAS test 296 2
Drug costs 12,824 23,6
Drug administration 5,191 3,3
Consultant monitoring appt. 1,397 1,4
CT scans 178 1
BSC in PD 5,304 3,4
Adverse events 3,671 2,7
Total 28,860 35,2
Cetuximab - BSC Pan
Life-years (mean, undiscounted)
Progression free 0.17
Postprogression 0.15
Total (mean) 0.32
Total (median) 0.35
QALYs (mean, discounted)
Progression free 0.14
Postprogression 0.10
Total 0.24
Costs (mean, discounted) (£)
KRAS test 300
Drug costs 12,800
Drug administration 5,200
Consultant monitoring appt. 1,400
CT scans 200
BSC in PD 1,800
Adverse effects 900
Total 22,600
Cost/life-year gained 72,000
Cost/QALY 95,000
BSC, best supportive care; CT, computed tomography; KRAS, Kirsten rat s
adjusted life-years.
* Uncertain because time on cetuximab plus irinotecan treatment not re
y Highly uncertain due to uncertainty in OS.
z Highly uncertain due to uncertainty in OS and because time on cetuxithe shortest time (0.36 years ¼ 4.3 months), panitumumab taken
for 0.49 years ¼ 5.8 months, and cetuximab plus irinotecan taken
for the longest time (0.73 years ¼ 8.8 months).
Next, we predict that people spend a similar time in PD on
BSC and panitumumab (0.29 years ¼ 3.4 months), longer in PD on
cetuximab (0.44 years ¼ 5.2 months), and longer still on cetux-
imab plus irinotecan (0.65 years ¼ 7.8 months). But note that the
time in PD on panitumumab is uncertain, because it is calculated
from OS for BSC in the panitumumab versus BSC RCT, which is
confounded because of crossover of people from the BSC to the
panitumumab arm. The time in PD on cetuximab plus irinotecan
is even more uncertain, because it is calculated from OS forutation.
mumab Cetuximab plus irinotecan BSC
0.49 0.73 NA
0.42 0.73 0.23
0.29 0.65y 0.29
0.71 1.38y 0.51
0.60 1.25y 0.40
0.33 0.54 0.17
0.19 0.43y 0.19
0.52 0.97y 0.36
96 296 0
43 32,022 0
74 12,714 0
79 2,533 0
88 322 0
73 7,790y 3,496
60 3,671 2,760
13 59,348 6,256
itumumab - BSC Cetuximab plus irinotecan – BSC
0.20 0.50
0.00 0.37y
0.19 0.87y
0.20 0.85y
0.16 0.37
0.00 0.24y
0.16 0.60y
300 300
23,600 32,000
3,400 12,700
1,500 2,500
200 300
0 4,300y
0 900
29,000 53,100
153,000 64,000z
187,000 88,000z
arcoma; OS, overall survival; PD, progressive disease; QALYs quality-
ported.
mab plus irinotecan treatment not reported.
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Fig. 1 – Cost-effectiveness acceptability curves. BSC, best supportive care; QALY, quality-adjusted life-year.
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OS, the sum of PFS and PD, is least for BSC (0.51 years ¼ 6.2
months), greater for cetuximab and panitumumab (0.84 and 0.71
years, or 10.0 and 8.5 months, respectively), and greatest for
cetuximab plus irinotecan (1.38 years ¼ 16.6 months), which, we
repeat, is very uncertain.
The incremental costs and quality-adjusted life-years (QALYs)
for cetuximab and panitumumab versus BSC are similar, whereas
these quantities are far greater for cetuximab plus irinotecan
(Table 5). The expected drug acquisition costs are by far the
largest single cost item (Table 5) and account for the largest
incremental costs versus BSC (Table 5). The expected drug
acquisition cost is least for cetuximab, at £12,800 per person,
because it is both the cheapest per person per unit time and it is
taken for the least time. The expected drug acquisition cost is
greatest for cetuximab plus irinotecan, at £32,000, because the
acquisition cost per unit of time is nearly as great as for
panitumumab and because we predict that it is taken for a far
longer period than are the other two treatments.
The expected drug administration costs and expected costs in
PD are the next largest single cost items (Table 5). Cost-
effectiveness is influenced more by expected drug administration
costs than by costs in PD, because these account for larger
incremental costs versus BSC (Table 5). The expected total drug
administration cost is least for panitumumab, at approximately
£3,400 per person, because it is easily the least expensive per
person per unit time (being taken relatively infrequently, every
2 weeks), and it is taken for much less time than cetuximab
plus irinotecan and for a similar time as cetuximab. The expected
total drug administration cost for cetuximab plus irinotecan is by
far the greatest, at £12,700, because it has the greatest adminis-
tration cost per unit of time (with two drugs to administer and
cetuximab given relatively frequently, every week) and because we
predict that it is taken for a far longer period than are the other two
treatments.
Absolute costs for BSC in PD are fairly large for all treatments
(between £3500 and £7800), but the incremental costs versus BSC
are small, with the exception of the cetuximab plus irinotecan
group, because the mean times spent in PD are fairly similar
between treatments, again with the exception of cetuximab plus
irinotecan. All other costs are all much smaller, and therefore
have very little impact on cost-effectiveness.
The net result is that we predict that panitumumab is
dominated by cetuximab monotherapy and cetuximab mono-
therapy is extended dominated by BSC and cetuximab plus
irinotecan. The incremental cost-effectiveness ratio (ICER) of
cetuximab plus irinotecan versus BSC is £88,000 per QALY.Sensitivity Analyses
One-way deterministic sensitivity analyses, which are reported in
the online Appendix in Supplemental Materials found at http://
dx.doi.org/%2010.1016/j.jval.2012.11.001, were chosen on the
basis of general interest (e.g., assuming no discounting), plausi
bility (e.g., varying mean PFS and OS by two standard errors), or
using assumptions from Merck Serono’s submission to NICE.
None of the sensitivity analyses brings the ICERs within NICE’s
willingness-to-pay thresholds.
The ICER for cetuximab versus BSC remains above £70,000 per
QALY gained in all cases. Cetuximab is usually extended domi-
nated but sometimes lies on the efficiency frontier. Estimated
cost-effectiveness is most sensitive to OS for BSC and cetuximab.
Cost-effectiveness is sensitive to mean PFS for cetuximab, when
we assume that this changes the mean duration of cetuximab
treatment proportionally and hence the cost of cetuximab acquisi-
tion. Estimated cost-effectiveness is fairly sensitive to the admin-
istration cost of cetuximab when this is varied within a plausible
range, because cetuximab is given regularly, once per week.
The ICERs for panitumumab versus BSC and cetuximab plus
irinotecan versus BSC remain very high, above £120,000 and
£55,000 per QALY gained, respectively, in all cases. Panitumumab
is always dominated, and cetuximab plus irinotecan and BSC
always lie on the efficiency frontier. The sensitivity of cost-
effectiveness to the various parameters is similar as for cetux-
imab versus BSC. In our base case, we predict that people take
both irinotecan and cetuximab for a mean of 0.73 years, that is,
nearly 9 months. We understand that irinotecan may typically be
tolerated by patients for a shorter period, given its toxicity.
Nonetheless, the cost-effectiveness of cetuximab plus irinotecan
remains high even when the durations of irinotecan or cetux-
imab and irinotecan are reduced.
The cost-effectiveness acceptability curves given in Figure 1
reveal that cetuximab and panitumumab are never predicted to
be the most cost-effective options, regardless of the willingness-
to-pay threshold. For a willingness to pay below about £85,000 per
QALY, BSC is likely to be the most cost-effective treatment, and
above £85,000 per QALY, cetuximab plus irinotecan is likely to be
most cost-effective.Conclusions
This is the first fully published study of the cost-effectiveness of
panitumumab and cetuximab plus irinotecan for third and
subsequent lines of treatment of patients with KRAS wild-type
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 8 8 – 2 9 6294metastatic colorectal cancer, and the first for cetuximab mono-
therapy in the United Kingdom. In our base-case analysis, we
predict that all three treatments—cetuximab, panitumumab, and
cetuximab plus irinotecan—are highly unlikely to be cost-
effective versus BSC in the United Kingdom at NICE’s usual
willingness-to-pay thresholds. We believe that the estimated
ICER for cetuximab versus BSC, at £95,000 per QALY gained, is
relatively accurate, because the relevant clinical effectiveness
evidence and duration of cetuximab treatment are both taken
from a high-quality RCT. The ICER for panitumumab versus BSC,
at £187,000 per QALY gained, is less certain because although
based on clinical effectiveness evidence from another high-
quality RCT, we rely on an adjustment for the crossing over of
many people from the BSC to the panitumumab treatment group,
which is associated with uncertainty. The ICER for cetuximab
plus irinotecan versus BSC, at £88,000 per QALY gained, is the
most uncertain because there is much uncertainty about PFS,
treatment duration, and OS for cetuximab plus irinotecan.
Together, this implies that our base-case result that panitumu-
mab is dominated is likely to be robust. The prediction, however,
that cetuximab is extended dominated is not robust. Instead,
cetuximab may lie on the efficiency frontier. Nonetheless, even
when key parameters are varied within plausible ranges, all three
treatments remain poor value for money.
Mittmann et al. also estimated that cetuximab monotherapy
provides poor value for money versus BSC in Canada for the same
patient population, with an ICER of $187,000 per QALY for people
with KRAS wild-type[5]. Adjusting their analysis for the price of
cetuximab used in our model, inflating costs to 2011, and using
an exchange rate of CAN $1.58 ¼ £1 gives an ICER of £101,000 per
QALY [12], similar to our estimate of £95,000 per QALY. In
contrast, in their submission to NICE, Merck Serono, the manu-
facturer of cetuximab, estimated a far lower ICER of £48,000 per
QALY for cetuximab versus BSC [12]. Although there are many
similarities between our model and that of Merck Serono, the
difference in estimated cost-effectiveness is almost entirely
caused by the large difference in total mean costs of acquisition
and administration of cetuximab: for drug acquisition, we esti-
mate £12,800, whereas Merck Serono estimate £8,200, and for
drug administration, we estimate £5,200, whereas Merck Serono
estimate £2,000 [12]. This itself is mostly because we estimate a
far longer mean time than Merck Serono on cetuximab treat-
ment: 0.36 years (4.3 months) versus 0.22 years (2.6 months) [12].
While our estimate is taken directly from the RCT of cetuximab
versus BSC, Merck Serono’s estimate is not justified [7].
The ICER of cetuximab versus BSC was recently estimated as
h66,000 per QALY for the Swiss health system [6], which equates to
£53,000 per QALY using an exchange rate of h1.24 ¼ £1. This is far
lower than the estimate of Mittmann et al. [5] for Canada and our
estimate of £95,000 per QALY for the United Kingdom. Blank et al.
[6] account for the difference between their model and that of
Mittmann et al. [5] by the fact that Mittmann et al. estimate
incremental QALYs as 0.19, less than half their value, 0.49. They
then suggest that this difference occurs because Mittmann et al.
restrict the time horizon for their analysis to the observation
period of the cetuximab versus BSC RCT, at which time approxi-
mately 20% of the patients were still alive [6], whereas they should
have extrapolated survival. While we agree that the difference in
cost-effectiveness between the Mittmann et al. and Blank et al.
models, and indeed between our model and the Blank et al. model,
is due to the differences in incremental QALYs, we think it unlikely
that this difference occurs because of whether survival is extra-
polated. Indeed, even though we extrapolate survival, we also
estimate far lower incremental QALYs, 0.24, compared with the
Blank et al. analysis of 0.49. Furthermore, it is impossible to
account for the difference in estimated cost-effectiveness between
our model and the Blank et al. model in the absence of a fullbreakdown of the results from the Blank et al. study in the manner
of our Table 5. Surprisingly, however, some important assumptions
used by Blank et al. actually act to make the cost-effectiveness
worse than in our model. First, Blank et al. assume a monthly cost
of cetuximab acquisition of h4840 ¼ £3900 in the first month and
h4208 ¼ £3400 in subsequent months, compared with our esti-
mates of £3400 and £3000. Next, they assume that cetuximab is
given until disease progression, whereas we assume that, on
average, it is stopped slightly before progression. Furthermore,
they assume a far lower utility in PD of 0.50, compared with our
0.69. It is possible that some of the difference in cost-effectiveness
is because Blank et al. estimated the critical parameters of mean
PFS and OS from just median PFS and median OS [6], whereas we
used regression to the underlying individual patient data.
The ICER for cetuximab plus irinotecan versus BSC from our
analysis, £88,000 per QALY, is also much higher than Merck Serono’s
£44,000 per QALY. As for the comparison for cetuximab versus BSC,
the difference is almost entirely due to the large difference in total
mean costs of acquisition and administration of cetuximab plus
irinotecan: for drug acquisition, we estimate £32,000, whereas
Merck Serono estimate £17,400, and for administration, we esti-
mate £12,700, whereas Merck Serono estimate £3,800 [12]. These
differences are due mostly to the fact that we estimate a far longer
mean time on cetuximab plus irinotecan treatment than Merck
Serono: 0.73 years (8.8 months), versus 0.37 years (4.4 months), and
we disagree with the derivation of their value [12].
The strengths of this assessment include that it was con-
ducted by an independent research team, which performed
comprehensive, explicit, and systematic literature searches to
locate evidence both for the review of clinical effectiveness and
to inform the economic modeling. In addition, the model was
extensively checked, and cost-effectiveness was estimated across
a range of plausible parameter values, and was compared with
other relevant economic models.
Weaknesses of our assessment include the lack of published
estimates of PFS, time on treatment, and OS for cetuximab plus
irinotecan, specifically for KRAS wild-type people. In addition, the
estimated cost-effectiveness of panitumumab versus BSC is uncer-
tain due to the confounded estimate of OS for BSC in the RCT of
panitumumab versus BSC due to substantial crossover of people
from BSC to panitumumab. Next, the relevance of the results to
actual clinical practice is uncertain given that we use efficacy data
from RCTs in which people are relatively young (median age
approximately 63 years) and fit (Eastern Cooperative Oncology Group
0–2), compared with people in actual clinical practice who are
typically older and less fit (some with Eastern Cooperative Oncology
Group 3–4). Finally, we have assumed that the proportion of patients
who are tested as being KRAS wild type who are truly wild type is
the same as in the RCTs of cetuximab versus BSC and panitumumab
versus BSC. We believe, however, that this is a reasonable assump-
tion given that the sensitivity and specificity of the most commonly
used KRAS mutation tests are both very high [12,26].
A growing number of jurisdictions require economic analyses
to inform the decision-making process for the reimbursement of
health technologies [27]. While our analysis was performed
specifically for the UK NHS, we believe that it can be adapted
simply for other countries. The approach for transferability is
likely to depend on two key factors: the decision-maker’s require-
ments and data availability [27]. The first step is to decide which
treatment comparators are relevant. For example, drug licenses
and the routine use of drugs can vary between jurisdictions [27].
The following parameters may differ between the country of
interest and the United Kingdom and are likely to have a
substantial impact on cost-effectiveness. Most important, the
appropriate figure in the row ‘‘Drug costs’’ in Table 5 should be
adjusted by multiplying by the ratio of the cost per milligram in
the country of interest to the cost per milligram for the United
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row in Table 5 is adjusted similarly by the relative cost per drug
administration. The ‘‘Consultant monitoring appt.,’’ ‘‘CT scans,’’
and ‘‘BSC in PD’’ rows should be adjusted similarly according to
the relative price per unit resource and the relative frequency per
resource between the countries.
The following parameters may differ between the country of
interest and the United Kingdom and are likely to have less impact
on cost-effectiveness. Cost-effectiveness is insensitive to the
discount rates for costs and benefits because life expectancy is
short. While the cost of treating adverse events may vary sub-
stantially, cost-effectiveness is insensitive to these. Nonetheless,
the row ‘‘Adverse events’’ in Table 5 can be adjusted accordingly.
There is debate about how and whether utilities should be
adjusted for specific countries [27]. Given the lack of detailed
information on utilities from the relevant trials, we recommend
that they be left unadjusted. The doses of all drugs depend either
on patient weight (panitumumab) or on body surface area (cetux-
imab and irinotecan). If these are likely to differ substantially from
the United Kingdom, the ‘‘Drug costs’’ in Table 5 should be
adjusted appropriately. Next, our analysis is performed from the
payer perspective. Other reimbursement agencies demand a
different perspective, for example, societal in Sweden. We believe,
however, that our analysis would need only minor changes,
because employment rates are likely to be low for all treatments,
given that patients have metastatic cancer. Last, the clinical
effectiveness data were taken from multinational RCTs for cetux-
imab [8] and panitumumab [4] and from a range of sources for
cetuximab plus irinotecan. Unfortunately, this is not reported by
country or region of the world; thus, simple adjustments to
effectiveness in the model are not possible. Sophisticated techni-
ques are available to estimate effectiveness by country; however,
these require access to the individual patient data [27].
We have identified two interesting methodological issues in
this analysis, and we recommend that they be considered in the
economic analyses of other health technologies for other condi-
tions. First, we based the indirect comparison of survival on
mean survival, whereas the hazard ratio is commonly used. We
recommend that mean survival be considered for the following
reasons. First, it is very simple. Second, cost-effectiveness is very
sensitive to mean survival. Indeed, for acute conditions, cost-
effectiveness is very insensitive to the statistical shape of the
survival distribution. Third, it does not require the proportional
hazards assumption, which is necessary when using the hazard
ratio. The second methodological issue concerns the estimation
of the mean dose per administration of intravenous drug per
patient. Traditionally, this is estimated according to the mean
patient body surface area or weight. As suggested by Sacco et al.
[21], however, it is more accurate, and we believe worthwhile, to
allow for the distribution of surface areas or weights across
patients, given that the amount of wastage varies according to
the individual patient and that the mean drug cost per patient is
always an important determinant of cost-effectiveness.Acknowledgments
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